• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Jaguar Health, Inc.

    1/11/22 4:10:50 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAGX alert in real time by email
    SC 13G 1 ea153861-13goasiscap_jaguar.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Jaguar Health, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    47010C409

    (CUSIP Number)

     

    Oasis Capital, LLC

    208 Ponce de Leon Ave Ste 1600

    San Juan, Puerto Rico 00918

    1-816-960-0100

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    January 11, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)
    ☒Rule 13d-1(c)
    ☐Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 47010C300   13G   Page 2 of 5 Pages

     

    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oasis Capital, LLC

    EIN # 66-0897157    

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)

     

    (a) ☐
    (b) ☐    

    3.   SEC USE ONLY
         
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America, Territory of Puerto Rico    

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    4,604,484
    6. SHARED VOTING POWER
     
    0
    7. SOLE DISPOSITIVE POWER
     
    4,604,484
    8. SHARED DISPOSITIVE POWER
     
    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  

     

    4,604,484    

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    (see instructions)   ☐

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99%1    

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    Accredited Investor    

     

     

    1This percentage is calculated based on approximately 46,090,931 shares of common stock outstanding of Jaguar Health, Inc. (the “Company”). Oasis Capital, LLC (“OASIS”) is deemed to beneficially own 9.99% of the common stock of the Company, as a result of OASIS’s equity purchase agreement, which gives OASIS the rights to own an aggregate number of shares of the Company’s common stock in an amount not to exceed 9.99% of shares of common stock then outstanding.

     

     

     

    CUSIP No. 47010C300   13G   Page 3 of 5 Pages

     

    Item 1.

     

     

     

    (a) Name of Issuer
    Jaguar Health, Inc.
         
      (b) Address of Issuer’s Principal Executive Offices
    200 Pine Street, Suite 400, San Francisco, CA 94101

     

    Item 2.

     

     

     

    (a) Name of Person Filing
    Oasis Capital, LLC
         
      (b) Address of the Principal Office or, if none, residence
    208 Ponce de Leon Ave Ste 1600, San Juan, Puerto Rico 00918
         
      (c) Citizenship
    United States of America
         
      (d) Title of Class of Securities
    Common Stock
         
      (e)

    CUSIP Number

    47010C300

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

    CUSIP No. 47010C300   13G   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:   4,604,484
           
      (b) Percent of class: 9.99%
           
      (c) Number of shares as to which the person has:  
           
        (i) Sole power to vote or to direct the vote   4,604,484
           
        (ii) Shared power to vote or to direct the vote  0
           
        (iii) Sole power to dispose or to direct the disposition of 4,604,484
           
        (iv) Shared power to dispose or to direct the disposition of  0

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

      

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

     

     

    Item 8. Identification and Classification of Members of the Group.

     

     

     

    Item 9. Notice of Dissolution of Group.

     

     

     

     

     

    CUSIP No. 47010C300   13G   Page 5 of 5 Pages

     

    Item 10. Certification.

     

      (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    January 11, 2022

    Date

     
     

    /s/ Adam Long

    Signature

       
     

    Adam Long, Managing Member

    Name/Title

     

     

     

     

     

    Get the next $JAGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAGX

    DatePrice TargetRatingAnalyst
    7/7/2021$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings